Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab with Salvage ASCT in Refractory Multiple Myeloma
NCT03173430Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in multiple myeloma (MM), sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 18 months. Started May 2017; status: terminated.
02
Drugs
blinatumomab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03173430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173430.